

R&D Day 2019 – Agenda

Time includes Q&A

	13:00-13:30	Opening Portfolio Overview	Vas Narasimhan John Tsai
Research Platforms	13:30-14:00	NIBR Cell Therapy, Gene Therapy, Molecular Glues	Jay Bradner
Emerging Assets	14:00-15:15	Pharmaceuticals TQJ230, LNP023, Iscalimab, Ligelizumab, Adriforant, LNA043, Tropifexor	Dave Soergel Eric Hughes
	15:15-15:45	Oncology MBG453, Asciminib, Canakinumab	Jeff Legos
	15:45-16:00	Break	
Late Stage & LCM Update	16:00-16:40	Pharmaceuticals Zolgensma [®] , Cosentyx [®] , Beovu [®] , Fevipiprant, Ofatumumab, <i>Inclisiran</i> , Entresto [®]	John Tsai
	16:40-17:30	Oncology Adakveo [®] , RLT platform, Piqray [®] , Kisqali [®] , Spartalizumab triplet, Kymriah [®]	Jeff Legos
	17:30-17:45	Closing	Vas Narasimhan
